Vista Pharmaceuticals Reports Widened Quarterly Loss, Reappoints Key Executives
Vista Pharmaceuticals Limited reported a net loss of Rs. 129.04 crore for Q1 FY2026, compared to Rs. 85.70 crore loss in Q1 FY2025. Revenue declined 15.4% to Rs. 151.88 crore. The company reappointed three key executives - Mr. Murali Meraga as Managing Director, Mr. Pavan Sathvik Gilaka and Mr. Dhananjaya Alli as Whole-time Directors for three-year terms. The 34th AGM is scheduled for September 30, 2025, via video conferencing. Book closure dates are set from September 24 to 30, 2025.